Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + docetaxel + TGFBi NK cells
- Development stage
- Unknown
- Lead developer
- Nationwide Children's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy, being evaluated in the TiNKS clinical trial (NCT05634369), is designed for the treatment of relapsed or refractory pediatric bone and soft tissue sarcomas. The regimen combines the standard salvage chemotherapy agents gemcitabine and docetaxel (often abbreviated as GEM/DOX in this specific trial context, which can lead to confusion with doxorubicin) with TGFβ-imprinted (TGFβi), ex vivo expanded, universal donor natural killer (NK) cells. The NK cells are a biologic immunotherapy modality that has been 'imprinted' during expansion by exposure to TGFβ to reduce their sensitivity to immunosuppression within the tumor microenvironment, thereby enhancing their cytotoxic potential. Developed by Nationwide Children's Hospital, the therapy aims to improve outcomes in patients aged 12-40 with difficult-to-treat cancers such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma by combining direct cytotoxic chemotherapy with adoptive cell transfer.
- Other names
- TGFβ-imprinted NK cellsTGFBi expanded NK cells
02
Targets
DNATGFB (GARP–latent transforming growth factor beta 1 complex)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + docetaxel + TGFBi NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + docetaxel + TGFBi NK cells.